SGHT News and Press, Sight Sciences Inc. From 09/13/22

310-patient RCT designed to evaluate the superiority of TearCare® (device) vs Restasis® (drug) in patients with chronic dry eye disease is now fully enrolled 6-Month efficacy results expected by Summer 2023 MENLO PARK, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sight S...

MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanle...

MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced the launch of SION , a surg...

Sight Sciences went public in July 2021, raising $240 million in an IPO. The firm develops and sells various surgical devices for treatment of glaucoma and dry eye conditions. Sight Sciences has produced growing revenue, but reimbursement is dropping for its lead product, and the ...

MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced 36-month post-surger...

Sight Sciences, Inc. (SGHT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call P...

Image source: The Motley Fool. Sight Sciences, Inc. (NASDAQ: SGHT) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Sight Sciences, Inc. (SGHT) Q2 2022 Earnings Call Transcript

Sight Sciences press release ( NASDAQ: SGHT ): Q2 GAAP EPS of -$0.50. Revenue of $17.23M (+37.5% Y/Y). Guidance: Sight Sciences projects revenue for the full year 2022 to range from $68M to $72M, which represents growth of approximately 39% to 47% compared to 2021. ...

MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June...

MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the ...